RevImmune is a privately held biotech company based in France, the U.S. and the U.K. RevImmune is in multiple Phase II trials with CYT107 for treatment of sepsis, certain infectious diseases and certain cancers. Over 440 patients have been treated with CYT107 in RevImmune's prior trials for multiple different viral diseases and sepsis. CYT107 showed an excellent safety profile and encouraging results in those trials.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.